WO2018138510A1 - Mébendazole utilisé dans le traitement du cancer - Google Patents
Mébendazole utilisé dans le traitement du cancer Download PDFInfo
- Publication number
- WO2018138510A1 WO2018138510A1 PCT/GB2018/050222 GB2018050222W WO2018138510A1 WO 2018138510 A1 WO2018138510 A1 WO 2018138510A1 GB 2018050222 W GB2018050222 W GB 2018050222W WO 2018138510 A1 WO2018138510 A1 WO 2018138510A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ran
- cancer
- mebendazole
- inhibitor
- tyrosine kinase
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 283
- 201000011510 cancer Diseases 0.000 title claims abstract description 177
- 238000011282 treatment Methods 0.000 title claims abstract description 140
- 229960003439 mebendazole Drugs 0.000 title claims description 195
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 title claims 24
- 102000005912 ran GTP Binding Protein Human genes 0.000 claims abstract description 212
- 108010005597 ran GTP Binding Protein Proteins 0.000 claims abstract description 212
- 239000003112 inhibitor Substances 0.000 claims abstract description 96
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 70
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 65
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 37
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims abstract description 12
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims abstract description 10
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 76
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 76
- 229960002584 gefitinib Drugs 0.000 claims description 76
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 74
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 55
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 55
- 229940121647 egfr inhibitor Drugs 0.000 claims description 49
- 102000001301 EGF receptor Human genes 0.000 claims description 45
- 108060006698 EGF receptor Proteins 0.000 claims description 45
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 31
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 24
- 208000020816 lung neoplasm Diseases 0.000 claims description 24
- 229960003278 osimertinib Drugs 0.000 claims description 24
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 24
- -1 or selected from Chemical class 0.000 claims description 23
- 238000002560 therapeutic procedure Methods 0.000 claims description 23
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 19
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 19
- 229960002448 dasatinib Drugs 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 17
- 230000002018 overexpression Effects 0.000 claims description 17
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 16
- 201000005202 lung cancer Diseases 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 14
- 229960001686 afatinib Drugs 0.000 claims description 10
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical group N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 10
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 10
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 7
- 229960001433 erlotinib Drugs 0.000 claims description 7
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 claims description 6
- 229950004272 brigatinib Drugs 0.000 claims description 6
- 229950007440 icotinib Drugs 0.000 claims description 6
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 5
- 229960001346 nilotinib Drugs 0.000 claims description 5
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 5
- 238000009097 single-agent therapy Methods 0.000 claims description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 4
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 4
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 4
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 4
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 4
- 229960003005 axitinib Drugs 0.000 claims description 4
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 4
- 229960003736 bosutinib Drugs 0.000 claims description 4
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 4
- 229960005061 crizotinib Drugs 0.000 claims description 4
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 4
- 229960001507 ibrutinib Drugs 0.000 claims description 4
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 4
- 229960002411 imatinib Drugs 0.000 claims description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 4
- 229960000639 pazopanib Drugs 0.000 claims description 4
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 4
- 229960004836 regorafenib Drugs 0.000 claims description 4
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- 229960001796 sunitinib Drugs 0.000 claims description 4
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 4
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 3
- 230000003827 upregulation Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 abstract description 19
- 150000003384 small molecules Chemical class 0.000 abstract description 14
- OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 description 174
- 210000004027 cell Anatomy 0.000 description 102
- 230000004083 survival effect Effects 0.000 description 45
- 239000000203 mixture Substances 0.000 description 34
- 230000000694 effects Effects 0.000 description 31
- 230000030279 gene silencing Effects 0.000 description 25
- 206010006187 Breast cancer Diseases 0.000 description 23
- 208000026310 Breast neoplasm Diseases 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- 108091008611 Protein Kinase B Proteins 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 108091007960 PI3Ks Proteins 0.000 description 18
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 18
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 18
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 229960003634 pimozide Drugs 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 210000000481 breast Anatomy 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 102100031506 Complement C5 Human genes 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 15
- 230000037361 pathway Effects 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 102100023132 Transcription factor Jun Human genes 0.000 description 13
- 238000001574 biopsy Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 12
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 230000002195 synergetic effect Effects 0.000 description 11
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 10
- 210000004940 nucleus Anatomy 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 238000007911 parenteral administration Methods 0.000 description 9
- 102000016914 ras Proteins Human genes 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 102000011781 Karyopherins Human genes 0.000 description 8
- 108010062228 Karyopherins Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000011260 co-administration Methods 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 108010014186 ras Proteins Proteins 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 8
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 201000005787 hematologic cancer Diseases 0.000 description 7
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000004393 prognosis Methods 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000003174 Brain Neoplasms Diseases 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101000668416 Homo sapiens Regulator of chromosome condensation Proteins 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 5
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 102100039977 Regulator of chromosome condensation Human genes 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 238000003197 gene knockdown Methods 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000000394 mitotic effect Effects 0.000 description 5
- 210000000633 nuclear envelope Anatomy 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 102000051485 Bcl-2 family Human genes 0.000 description 4
- 108700038897 Bcl-2 family Proteins 0.000 description 4
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 4
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 4
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 4
- 240000007472 Leucaena leucocephala Species 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 4
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 4
- 101150084062 RAN gene Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 4
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000005735 apoptotic response Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 102000003998 progesterone receptors Human genes 0.000 description 4
- 108090000468 progesterone receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 3
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 101710122673 Ran GTPase-activating protein Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 3
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000001808 exosome Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 229950008001 matuzumab Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229950010203 nimotuzumab Drugs 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229960001972 panitumumab Drugs 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000000861 pro-apoptotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000020347 spindle assembly Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 229950008250 zalutumumab Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- 101150107888 AKT2 gene Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108700022174 Drosophila Son of Sevenless Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 2
- 239000004150 EU approved colour Substances 0.000 description 2
- 101150039808 Egfr gene Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 2
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108060006678 I-kappa-B kinase Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 2
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 2
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 102100028418 Nuclear transport factor 2 Human genes 0.000 description 2
- 101710159639 Nuclear transport factor 2 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 2
- 102000004422 Phospholipase C gamma Human genes 0.000 description 2
- 108010056751 Phospholipase C gamma Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 101150045355 akt1 gene Proteins 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000000921 anthelmintic agent Substances 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000035572 chemosensitivity Effects 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 125000004431 deuterium atom Chemical group 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 206010014881 enterobiasis Diseases 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004547 gene signature Effects 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940074045 glyceryl distearate Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 229940127082 non-receptor tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000006849 nucleocytoplasmic transport Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 101000609447 Beet necrotic yellow vein virus (isolate Japan/S) Protein P25 Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
- 101100301096 Drosophila melanogaster Nup358 gene Proteins 0.000 description 1
- 102100038912 E3 SUMO-protein ligase RanBP2 Human genes 0.000 description 1
- 101710198453 E3 SUMO-protein ligase RanBP2 Proteins 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 241000401950 Felinae Species 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102100022887 GTP-binding nuclear protein Ran Human genes 0.000 description 1
- 101710084647 GTP-binding nuclear protein Ran Proteins 0.000 description 1
- 102220616641 GTP-binding nuclear protein Ran_G19V_mutation Human genes 0.000 description 1
- 102220614800 GTP-binding nuclear protein Ran_Q69L_mutation Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 238000011460 HER2-targeted therapy Methods 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
- 101710184069 Hepatocyte growth factor receptor Proteins 0.000 description 1
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101100456626 Homo sapiens MEF2A gene Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000830894 Homo sapiens Targeting protein for Xklp2 Proteins 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101150071228 Lifr gene Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 101150058160 Lyn gene Proteins 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 1
- 101150105382 MET gene Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 101100079042 Mus musculus Myef2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100021148 Myocyte-specific enhancer factor 2A Human genes 0.000 description 1
- 102100039212 Myocyte-specific enhancer factor 2D Human genes 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000003789 Nuclear pore complex proteins Human genes 0.000 description 1
- 108090000163 Nuclear pore complex proteins Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 101100338491 Oryza sativa subsp. japonica HCT1 gene Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 101150058731 STAT5A gene Proteins 0.000 description 1
- 101100495309 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDH1 gene Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 101100174184 Serratia marcescens fosA gene Proteins 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 241000244177 Strongyloides stercoralis Species 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102000004398 TNF receptor-associated factor 1 Human genes 0.000 description 1
- 108090000920 TNF receptor-associated factor 1 Proteins 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
- 102100024813 Targeting protein for Xklp2 Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010071990 Tyrosine kinase mutation Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 108010007734 bcl-Associated Death Protein Proteins 0.000 description 1
- 102000007348 bcl-Associated Death Protein Human genes 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000008777 canonical pathway Effects 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Chemical group 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 101150078861 fos gene Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000009629 growth pathway Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000044042 human KLRK1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002415 kinetochore Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 101150014102 mef-2 gene Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000006348 regulation of epithelial to mesenchymal transition Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220058924 rs749212640 Human genes 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007046 spindle assembly involved in mitosis Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000007755 survival signaling Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000016853 telophase Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to mebendazole or a pharmaceutically acceptable form thereof for use as an inhibitor of RAN, for example for use in the treatment of a cancer that overexpresses RAN or its protein product Ran.
- Overexpression of RAN may be characteristic of the cancer type or may be stimulated by prior cancer therapy.
- Neoplasm can be benign or malignant (cancerous) and are often referred to as tumours.
- tumour is used to refer to malignant (cancerous) neoplasms.
- tumours and the treatment of cancer have the same meaning herein, while reference to breast cancer or breast tumour, and treatment thereof, refers to a cancer or tumour that originates in the breast, or treatment thereof, rather than a tumour that originates in another organ and that has spread to the breast through the process of metastasis.
- Tumours or cancers that originate in other organs or sites are referred to in a similar manner.
- Tumours that are derived from the process of metastasis are referred to as metastases or secondary tumours.
- cancer cells stimulate their own growth; (ii) cancer cells resist inhibitory signals that might otherwise stop their growth; (iii) cancer cells resist their programmed ceil death (they evade apoptosis); (iv) cancer ceils can multiply indefinitely; (v) cancer ceils stimulate the growth of blood vessels to supply nutrients to tumours (angiogenesis); and (vi) cancer ceils invade local tissue and spread to distant sites (metastasis).
- cancer ceils Whether or not the full set of hallmarks, that have subsequently been supplemented ("Hallmarks of Cancer; The Next Generation" Cell 44 (5): 646-674), are exhibited by all cancers, it is apparent that targeting one or more of these hallmarks affords an opportunity to exert a selective killing effect on cancer cells.
- Cancer cells are addicted to oncogenes or oncogenic pathways (Weinstein, Science 2002;297:83-4), which are usually uniquely present or hyperactivated, and are essential for tumour ceil growth and survival.
- the two most frequently dysreguiated signaling pathways in cancers are the phosphoinositide 3-kinase (PI3K)/Akt/mTQRC1 and Ras/ EK/ERK [mitogen- activated protein/extracellular signal-regulated kinase (ERK; EK)] pathways (Grant, J Clin invest 2008; 1 13:3003-8).
- Tumours or cancers are commonly referred to by the primary site of their occurrence, i.e. where the tumour first develops, and often also by reference to further characteristics, for example whether their growth is stimulated by hormones or whether they express certain receptors.
- primary tumours located in the breast are referred to breast cancers while tumours whose growth is stimulated by hormones such as estrogen, progesterone and testosterone are referred to as hormone dependent cancers.
- breast cancers whose growth is stimulated by the presence of estrogen are known as estrogen receptor positive (ER+ve) breast cancers.
- ER+ve estrogen receptor positive
- progesterone receptor positive (PR+ve) breast cancers breast cancers that express progesterone receptors and whose growth is sensitive to the presence of progesterone are referred to as progesterone receptor positive (PR+ve) breast cancers whilst those whose growth is independent of the expression of progesterone receptor are progesterone receptor negative (PR-ve) breast cancers.
- HER2-positive breast cancer a subset of breast cancers that overexpress human epidermal growth factor 2.
- HER2 targeted therapies examples include the anti-HER2 antibodies trastuzumab and pertuzumab and the antibody-drug-conjugate trastuzumab emtansine.
- triple negative breast cancers those tumour types whose growth is independent of ER, PR or HER2 status, are commonly referred to as triple negative breast cancers. Patients suffering from triple negative breast cancers presently have the worst overall and disease-free survival rates. Treatment options for patients with triple negative breast tumours are relatively limited (Ontilo et al, Clin Med Res. 2009 Jun; 7(1-2): 4-13) with the present treatment paradigms usually involving a combination of surgery and radiation as appropriate with cytotoxic chemotherapy with agents such as anthracyclines, taxanes or platinum chemotherapeutic agents, such as carboplatin, unless the patient has a tumour with a BRCA1 mutation.
- cytotoxic chemotherapy with agents such as anthracyclines, taxanes or platinum chemotherapeutic agents, such as carboplatin, unless the patient has a tumour with a BRCA1 mutation.
- Tyrosine kinases are enzymes responsible for the activation, via phosphorylation, of many proteins by signal transduction cascades. Inhibition of tyrosine kinases has proven to be a successful therapeutic approach from the treatment of a number of cancer types and drugs that selectively inhibit specific tyrosine kinases have been developed.
- the Bcr- Abl tyrosine kinases inhibitor nilotinib is used to treat chronic myelogenous leukaemia
- the epidermal growth factor receptor tyrosine kinase (EGFR/ ErbB-1) inhibitor gefitinib is used for the treatment of certain breast and lung cancers, especially for patient with EGFR mutations.
- RAN a member of the RAS Oncogene family
- RAS Oncogene is a gene that encodes the GTP-binding nuclear protein Ran.
- Overexpression of RAN gene is observed in a number of cancers and this overexpression has been linked to poor patient prognosis.
- RAN overexpression has been shown to correlate with increased aggressiveness of cancer cells in vitro and in vivo (Kurisetty et al, Oncogene 2008, 27, 7139-49), i.e. RAN overexpressing cancer cells are seen to grow rapidly and exhibit high metastatic potential.
- silencing RAN by siRNA or shRNA reduced cell adhesion, migration and invasion in vitro and metastasis in vivo.
- RAN silencing the RAN gene with siRNA or shRNA induces a greater degree of apoptosis in cancer cells relative to that induced in normal cells and in activated KRas-mutant cells relative to their isogenic KRas wild-type counterparts. Cancer cells are observed to be more sensitive to changes in RAN status than their normal counterparts. RAN silencing has also been observed to promote apoptosis in cancer cells with mutations that correlate with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK signalling pathways (Yuen et al, Clin Cancer Res 201 1 ; 18(2); 1-12). As a result, RAN has been suggested as a potential therapeutic target for cancer phenotypes in which the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways are activated.
- Ran Ras-related nuclear protein, a 25-kDa protein product encoded by RAN gene, is a G- protein GTPase that cycles between a GDP-bound (RanGDP) and a GTP-bound (RanGTP) state that regulates nucleocytoplasmic transport, mitotic spindle fibre assembly and post- mitotic nuclear envelope dynamics.
- Ran exists in a different conformation depending on whether it is bound to GTP or GDP. in its GTP bound state, Ran is capable of binding karyopherins (importins and exportins) a set of proteins that are involved in importing and exporting molecules between the nucleus and the cytoplasm of a eukaryotic ceil, importins release a molecular cargo upon binding to RanGTP in the nucleus, while exportins must bind RanGTP in the nucleus to form a ternary complex with their export cargo in order to transport the cargo to the cytoplasm.
- karyopherins importins and exportins
- the dominant nucleotide binding state of Ran depends on whether it is located in the nucleus (RanGTP) or the cytoplasm (RanGDP), with RanGTP being formed inside the nucleus through interaction of Ran with its specific guanine nucleotide exchange factor (GEF), regulator of chromosome condensation 1 referred to herein as RCC1 , which catalyses the exchange of GDP for GTP on the nucleotide binding pocket of Ran.
- GEF guanine nucleotide exchange factor
- RCC1 regulator of chromosome condensation 1
- Hydrolysis of RanGTP to RanGDP in the cytoplasm by RanGAP and RanBPI releases energy and causes the ternary complex of Ran, exportin and cargo to dissociate thus releasing the cargo exported from the nucleus.
- Cytoplasmic RanGDP is in turn imported into the nucleus by the small protein NTF2 (Nuclear Transport Factor 2), where RCC1 can then catalyse exchange of GDP for GTP on Ran and
- the Ran cycle is involved in mitotic spindle assembly and nuclear envelope reassembly after the chromosomes have been separated.
- the steep gradient in RanGTP-RanGDP ratio at the nuclear pores breaks down as the nuclear envelope becomes leaky and disassembles.
- RanGTP concentration stays high around the chromosomes as RCC1 stays attached to chromatin as the nucleoporin RanBP2 (Nup358) and Ran GTPase activating protein (RanGAP) move to the kinetochores where they facilitate the attachment of spindle fibres to chromosomes.
- RanGTP promotes spindle assembly by mechanisms similar to mechanisms of nuclear transport: the activity of spindle assembly factors such as NuMA and TPX2 is inhibited by the binding to importins. By releasing importins, RanGTP activates these factors and therefore promotes the assembly of the mitotic spindle.
- RanGTP hydrolysis and nucleotide exchange are required for vesicle fusion at the reforming nuclear envelopes of the daughter nuclei.
- Ran expression was independently associated with patient survival times in Cox-regression analyses.
- Stable transfection of non-invasive mammary cells with an expression vector for Ran (R37-Ran and MCF-1 OA-Ran) was found to induce an invasive/metastatic phenotype in vitro and the development of metastases in vivo (Kurisetty VV, El-Tanani MK et al. Oncogene. 2008,27(57) :7139-49).
- Stable transfection of invasive cells MDA-MB-231 , R37-OPN and R37-RAN
- siRNA directed at Ran specifically inhibits the invasive/metastatic phenotype in vitro and in vivo (Kurisetty VV, El-Tanani MK et al. Oncogene.
- Ran silencing was found to induce a significant apoptotic response in GR5 c-Met amplified cells in the presence of gefitinib, but not in HCC827 parental cells (p ⁇ 0.01), suggesting that Ran silencing may be used as a modulator of chemosensitivity (Yuen HF, El-Tanani M, et al. J Natl Cancer Inst. 2013; 105(7):475-88).
- TKI EGFR tyrosine kinase inhibitors
- Osimertinib was developed to treat T790M mutation-positive NSCLCs. Exploration of novel approaches to further enhance the therapeutic efficacy of TKIs in such patient cohorts aimed at improving progression-free and overall survival times remains an important challenge.
- Diseases overexpressing RAN include but are not limited to certain breast, lung, prostate, ovarian, blood, brain and renal cancers as well as certain cancers currently associated with poor patient prognosis such as triple negative breast cancer.
- mebendazole or a pharmaceutically acceptable form thereof, for use as an inhibitor of RAN at a transcriptional level.
- the mebendazole for use as an inhibitor of RAN at a transcriptional level is for use in the treatment of cancer, for example a cancer that overexpresses RAN or its protein product Ran.
- the mebendazole for use as an inhibitor of RAN at a transcriptional level in the treatment of cancer is for use in patients identified as having a cancer that overexpresses RAN, for example a cancer that overexpresses Ran mRNA, or its protein product Ran.
- the mebendazole for use is used in the treatment of breast, lung, prostate, ovarian, blood, brain and renal cancers including those cancers currently associated with poor patient prognosis such as triple negative breast cancer.
- a cancer that overexpresses RAN may overexpress Ran mRNA and/or Ran protein and may be identified, for example, by establishing that elevated levels of Ran mRNA and/or Ran protein are present in the cancer cells. Note that not all cancers within a particular cancer type or sub-type will overexpress RAN.
- the invention also provides a Ran inhibitor, i.e. a compound capable of inhibiting RAN, for example at a transcriptional level, or its protein product Ran, for example a small molecule inhibitor of RAN at a transcriptional level such as mebendazole or pimozide (as described in UK patent application No. GB1616880.9) or a protein inhibitor of the Ran / RCC-1 interaction (as described in UK patent application No. GB1607593.9), for use in combination with a tyrosine kinase inhibitor, such as a small molecule or an antibody tyrosine kinase inhibitor, for the treatment of cancer.
- a tyrosine kinase inhibitor such as a small molecule or an antibody tyrosine kinase inhibitor
- tyrosine kinase inhibitors that may be used in combination with a RAN inhibitor for the treatment of cancer include afatinib (GiotrifTM), axitinib (InlytaTM), bosutinib (BosulifTM), crizotinib (XalkoriTM), dasatinib (SprycelTM), erlotinib (Tarceva), gefitinib (IressaTM), osimertinib (TagrissoTM), imatinib (GlivecTM), lapatinib (TyverbTM), nilotinib (TasignaTM), pazopanib (VotrientTM), regorafenib (StivargaTM), sorafenib (NexavarTM), sunitinib (SutentTM) and ibrutinib (ImbruvicaTM).
- afatinib GaotrifTM
- the inhibitor of RAN for use with a tyrosine kinase inhibitor is an inhibitor of RAN at a transcriptional level such as mebendazole.
- mebendazole is used as an inhibitor of RAN in combination with an inhibitor of an epidermal growth factor receptor (EGFR) tyrosine kinase such as the small molecules gefitinib, erlotinib, afatinib, brigatinib, icotinib, or osimertinib or the antibodies cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab.
- EGFR epidermal growth factor receptor
- EGFR inhibitors Molecules and antibodies that inhibit epidermal growth factor receptor (EGFR) tyrosine kinase are generally referred to herein as EGFR inhibitors.
- the co-administration of mebendazole and an EGFR inhibitor may be simultaneous, sequential or separate. It has been demonstrated that the combination of mebendazole and an EGFR inhibitor has a synergistic effect against cancer cell proliferation. It has also been shown that mebendazole can restore sensitivity of gefitinib resistant cancer cells to gefitinib treatment therefore providing a new therapeutic approach for the treatment of patients who have progressed on EGFR inhibitor therapy and, potentially, a new mechanism to prevent development of EGFR inhibitor resistance.
- Identification of the patients indicated for mebendazole treatment i.e. those having a cancer that overexpresses RAN, its protein product Ran or its target pathways including c-myc, c- Met, osteopontin, PI3K/AKT/mTORC and KRas/MEK/ERK1/2 may be achieved by obtaining a sample from the candidate patient, for example a tumour biopsy or a blood sample, and analysing the sample for high expression of Ran mRNA or protein or a biomarker for Ran expression.
- the patient identification may involve testing for c- Met amplification, PI3K/AKT/mTORC and KRas/MEK/ERK1/2 or mutation status of a tyrosine kinase such as EGFR.
- a tumour biopsy sample can be stained with a stain comprising a RAN selective antibody linked to a visualising means such as an enzyme or fluorophore.
- the stained tumour biopsy can then be categorised as a RAN overexpressing tumour or a non-RAN overexpressing tumour. This categorisation can be done by a visual or automated scoring.
- Testing for tyrosine kinase mutation status can be by the methods available in the art, for example the commercially available testing kits produced by Genzyme, QIAGEN and Argenomics S.A.
- Analysis of a patient blood sample to determine whether a patient has a RAN overexpressing tumour may be performed by isolating the serum exosome and then carrying out an ELISA (to assess Ran protein expression) or quantitative real time PCR (q RT-PCR, to detect RNA expression) analysis to provide the necessary tumour/patient classification.
- the patient is a human patient.
- the mebendazole for use is administered in a dosage of from 1 to 5000 mg/day.
- the invention also relates to a method of treatment of a cancer that overexpresses RAN (or Ran mRNA) or its protein product Ran, comprising a step of administering to a patient in need thereof an effective amount of mebendazole or a pharmaceutically acceptable form thereof.
- This method of treatment may further comprise a step of testing a sample obtained from said patient to determine whether said patient has a RAN overexpressing cancer prior to said administration step.
- the invention also provides a method of treatment of a cancer that overexpresses RAN (or Ran mRNA), or its protein product Ran, comprising the step of administering to a patient who has been identified as having a cancer that overexpresses RAN, or its protein product Ran, an effective amount of mebendazole or a pharmaceutically acceptable form thereof.
- This method of treatment may further comprise a step of testing a sample obtained from said patient to determine whether said patient has a RAN overexpressing cancer prior to said administration step.
- the invention also provides a method of treatment of a cancer that overexpresses RAN, (or Ran mRNA) or its protein product Ran, comprising the steps of selecting a patient who has a cancer that overexpresses RAN or its protein product Ran, and administering an effective amount of mebendazole or a pharmaceutically acceptable form thereof to that patient.
- This method of treatment may further comprise a step of testing a sample obtained from said patient to determine whether said patient has a RAN overexpressing cancer prior to said administration step.
- the invention also provides a method of treatment for cancer in a patient diagnosed as having a cancer characterised by an overexpression of RAN or its protein product Ran involving administration to a patient in need thereof an effective amount of mebendazole.
- the cancer characterised by an overexpression of RAN may be triple negative breast cancer.
- the cancer characterised by an overexpression of RAN may be lung cancer, and in particular lung cancers that have previously been treated with a tyrosine kinase inhibitor, for example wherein the previous treatment involved administration of an tyrosine kinase inhibitor such as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor such as gefitinib, erlotinib, afatinib, brigatinib, icotinib or osimertinib to a lung cancer patient and wherein the disease no longer responds to the treatment with the EGFR inhibitor.
- EGFR epidermal growth factor receptor
- Such methods may involve co- administration of the previously used tyrosine kinase inhibitor with a Ran inhibitor, in particular wherein the Ran inhibitor is mebendazole.
- the invention also provides a method of treatment for cancer in a patient diagnosed as having a cancer characterised by an overexpression of a tyrosine kinase, such as a mutated tyrosine kinase, such as epidermal growth factor receptor (EGFR) tyrosine kinase, involving administering mebendazole in combination with an inhibitor of the tyrosine kinase that is overexpressed, for example in a cancer with a mutation in the EGFR tyrosine kinase domain, an EGFR inhibitor may be used.
- the administration of mebendazole and an EGFR inhibitor may be simultaneous, sequential or separate.
- the combination of mebendazole and an EGFR inhibitor may prevent or substantially delay the emergence of resistance to the EGFR inhibitor associated with EGFR inhibitor monotherapy.
- the combination of mebendazole and an EGFR inhibitor may resensitize a tumour to treatment with an EGFR inhibitor to which the patient no longer responds as a monotherapy.
- the invention also provides mebendazole for use as an immunotherapy, for example for the treatment of cancer, for instance by down regulating C5a.
- the invention relates to the use of mebendazole, or a pharmaceutically acceptable form thereof, for the manufacture of a medicament for the treatment of cancer, optionally wherein the cancer overexpresses RAN or its protein product Ran.
- the resultant medicament may be provided in a package with instruction for use in the treatment of a cancer that overexpresses RAN or its protein product Ran.
- the resultant medicament may be provided in a package with instruction for use in combination with an EGFR inhibitor such as gefitinib.
- the invention provides a package comprising mebendazole or a pharmaceutically acceptable form thereof and instructions for its use in the treatment of a cancer that overexpresses RAN or its protein product Ran or instructions for its use in the treatment of a cancer that overexpresses epidermal growth factor receptor (EGFR) tyrosine kinase.
- EGFR epidermal growth factor receptor
- Figure 1 shows the effects of drug treatment on A) cell morphology and B) survival of HCC827 lung cancer cells on exposure to control (DMSO), mebendazole (0.1 ⁇ , 0.5 ⁇ , 1 ⁇ ), gefitinib (1 ⁇ ) and dasatinib (1 ⁇ ) and combinations of gefitinib and dasatinib with mebendazole.
- Figure 2 shows the effects of drug treatment on A) cell morphology and B) survival of HCC827 GR5 (gefitinib resistant) lung cancer cells on exposure to control (DMSO), mebendazole (0.1 ⁇ , 0.5 ⁇ , 1 ⁇ ), gefitinib (1 ⁇ ) and dasatinib (1 ⁇ ) and combinations of gefitinib and dasatinib with mebendazole.
- DMSO control
- mebendazole 0.1 ⁇ , 0.5 ⁇ , 1 ⁇
- gefitinib (1 ⁇ ) and dasatinib (1 ⁇ ) and combinations of gefitinib and dasatinib with mebendazole.
- Figure 3 shows the relative gene expression (fold change) in HCC827 cells treated with mebendazole (0.1 ⁇ , 0.5 ⁇ ) for 24h relative to control.
- Figure 4 shows the relative gene expression (fold change) in HCC827 GR5 (gefitinib resistant) cells treated with mebendazole (0.1 ⁇ , 0.5 ⁇ ) for 24h relative to control.
- Figure 5 show the results of immunoblotting for A) Ran (28 kDa, rabbit, 1 :3000 dil in 5% milk powder), B) pBad (27 kDa, mouse, 1 :3000 dil in 5% BSA), C) Actin (40 kDa, mouse, 1 : 10 000 dil in 5% milk powder) in the lysate obtained from HCC827 GR5 cells treated with 1) Control (DMSO), 2) 1 ⁇ Gefitinib, 3) 300 nM osimertinib, 4) 100 nM mebendazole, 5) 100 nM mebendazole + 1 ⁇ Gefitinib, 6) 100 nM mebendazole + 300 nM osimertinib, 7) 500 nM mebendazole, 8) 500 nM mebendazole + 1 ⁇ Gefitinib and 9) 500 nM mebendazole + 300 nM os
- Figure 6 shows the effect on HCC827 human cancer cell survival following treatment with A) gefitinib, B) pimozide and C) various concentrations of pimozide in combination with 300 nM gefitinib.
- Figure 7 shows the effect on HCC827 GR5 (gefitinib resistant) human cancer cell survival following treatment with A) gefitinib B) pimozide and C) various concentrations of pimozide in combination with 300 nM gefitinib.
- the present invention relates to mebendazole, or a pharmaceutically acceptable form thereof, for use as a Ran inhibitor for the treatment of cancer, for example in patients identified as having a cancer that overexpresses RAN or Ran, for example a cancer in which atypically high elevated levels of Ran mRNA and/or Ran protein are present in the cancerous cells.
- Ran a protein product of the gene RAN, is a member of the Ras superfamily that regulates nucleocytoplasmic transport, mitotic spindle fibre assembly and post-mitotic nuclear envelope dynamics. Ran acts as a molecular switch through a GTP-GDP cycle in which the conversion between GTP-bound and GDP-bound conformations controls its interaction with different effectors.
- RanGTP is formed inside the nucleus by interaction of Ran with its specific guanine nucleotide exchange factor (GEF), referred to herein as RCC1 , which catalyses the exchange of GDP for GTP (and vice versa) on the nucleotide binding pocket of Ran.
- GEF guanine nucleotide exchange factor
- RAN, and its protein product Ran are known to be overexpressed in a number of cancers including those in which the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways are activated.
- Diseases overexpressing Ran include but are not limited to certain breast, lung, prostate, ovarian, blood, brain and renal cancers as well as certain cancers currently associated with poor patient prognosis such as triple negative breast cancer.
- Mebendazole methyl (5-benzoyl-1 H-benzimidazol-2-yl)carbamate (Formula I below), is a broad spectrum antihelmintic drug sold under trade names such as VermoxTM and EmvermTM indicated for the treatment of nematode infestations, including roundworm, hookworm, whipworm, threadworm, pinworm, and the intestinal form of trichinosis prior to its spread into the tissues beyond the digestive tract.
- mebendazole as an antihelmintic agent is thought to stem from selective inhibition of the synthesis of microtubules in parasitic worms through binding at the colchicine site of tubulin. Destruction of extant cytoplasmic microtubes in the worm intestinal cells, blocks the uptake of glucose and other nutrients, resulting in the gradual immobilization and eventual death of the helminths.
- mebendazole has activity against the proliferation of cancers cells in in vivo and in vitro models of cancer (see e.g. Mukhopadhyay et al, Clin Cancer Res 8(9) 2963-9).
- mebendazole could inhibit RAN or production of its protein product Ran, nor was it known that mebendazole inhibits RAN at a transcriptional level.
- the identification of mebendazole as a Ran inhibitor that acts by inhibiting RAN at a transcriptional level, thereby suppressing the downstream effects of the RAN gene, for example Ran mRNA expression provides a new and advantageous option for therapy of patients with cancers that overexpress RAN or its protein product Ran.
- the present invention advantageously allows identification of groups of cancer patients that are indicated for mebendazole treatment and advantageously allows a therapeutic intervention for such patients that is targeted to the genetic profile of their cancer.
- the present invention thus potentially provides for improved therapeutic outcomes for cancer patients with cancers including solid and blood cancers (including solid and blood cancers, e.g. acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, lymphoma and myeloma) that overexpress RAN and its protein product Ran.
- solid and blood cancers including solid and blood cancers, e.g. acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, lymphoma and myeloma
- the invention provides mebendazole, or a pharmaceutically acceptable form thereof, for use as an inhibitor of RAN at a transcriptional level.
- the mebendazole for use as an inhibitor of RAN at a transcriptional level is for use in the treatment of cancer, for example a cancer that overexpresses RAN or its protein product Ran.
- the mebendazole for use as an inhibitor of RAN at a transcriptional level in the treatment of cancer is for use in patients identified as having a cancer that overexpresses RAN or its protein product Ran.
- cancer types that are known to overexpress RAN or its protein product Ran, and for which mebendazole as a Ran inhibitor is indicated for use include, but are not limited to certain breast, lung, prostate, ovarian, bladder, colorectal, blood, brain and renal cancers as well as certain cancers currently associated with poor patient prognosis such as triple negative breast cancer.
- the selection of patients to be treated with mebendazole for use according to the invention is advantageously performed by establishing that they have a cancer that overexpresses RAN or its protein product Ran. This selection may be performed by obtaining a sample from the candidate patient, for example a tumour biopsy or a blood sample, and analysing the sample for the presence of RAN or a biomarker for RAN expression.
- a tumour biopsy sample can be stained with a stain comprising a RAN selective antibody linked to a visualising means such as an enzyme or fluorophore.
- the stained tumour biopsy can then be categorised as a RAN overexpressing tumour or a non-RAN overexpressing tumour. This categorisation can be done by a visual or automated scoring.
- the present invention also relates to a Ran inhibitor, for example mebendazole, for use in combination with a tyrosine kinase inhibitor, for example a receptor tyrosine kinase inhibitor such as an inhibitor of EGFR tyrosine kinase or a non-receptor tyrosine kinase inhibitor such as a Bcr-Abl kinase inhibitor, for the treatment of cancer.
- a tyrosine kinase inhibitor for example a receptor tyrosine kinase inhibitor such as an inhibitor of EGFR tyrosine kinase or a non-receptor tyrosine kinase inhibitor such as a Bcr-Abl kinase inhibitor
- receptor tyrosine kinases inhibitors that may be used in combination with a Ran inhibitor such as mebendazole include inhibitors of PDGFR and FGFR kinases.
- Other non-receptor tyrosine kinases inhibitors that may be used in combination with a Ran inhibitor such as mebendazole include inhibitors of SRC, FAK and JAK.
- Other Ran inhibitors such as small molecule, peptide, protein or antibody inhibitors of Ran, may be used in conjunction with a tyrosine kinase inhibitor.
- a new approach for the treatment of cancers that are indicated for tyrosine kinase inhibitor therapy involves co-administration of the appropriate tyrosine kinase inhibitor with a Ran inhibitor.
- the Ran inhibitor may be a small molecule inhibitor of RAN at a transcriptional level such as mebendazole or pimozide, a peptide inhibitor of the Ran / RCC- 1 interaction or an antibody.
- the tyrosine kinase inhibitor may be as a small molecule or an antibody tyrosine kinase inhibitor.
- tyrosine kinase inhibitors that may be used in combination with a Ran inhibitor for the treatment of cancer include afatinib (GiotrifTM), axitinib (InlytaTM), bosutinib (BosulifTM), crizotinib (XalkoriTM), dasatinib (SprycelTM), erlotinib (Tarceva), gefitinib (IressaTM), osimertinib (TagrissoTM), imatinib (GlivecTM), lapatinib (TyverbTM), nilotinib (TasignaTM), pazopanib (VotrientTM), regorafenib (StivargaTM), sorafenib (NexavarTM), sunitinib (SutentTM) and ibrutinib (ImbruvicaTM).
- afatinib GaotrifTM
- the Ran inhibitor for use with a tyrosine kinase inhibitor is an inhibitor of RAN at a transcriptional level such as mebendazole.
- the co-administration of a Ran inhibitor and tyrosine kinase inhibitor may be simultaneous, sequential or separate.
- c-MET amplification which leads to activation of the PI3K/AKT and MEK/ERK pathway promotes gefitinib resistance in lung cancer cells.
- Gefitinib-resistant cells, with c-Met amplification have been shown to have an increased apoptotic response to Ran silencing compared to their wild-type counterparts, indicating that cells with c-MET amplification are more susceptible to apoptosis in the presence of Ran silencing. These results were confirmed using a MTT cell survival assay. Furthermore, inhibition of the PI3K/AKT and RAS/MEK/ERK pathways significantly reduced c-MET-mediated sensitization to Ran knock-down (p ⁇ 0.01).
- mebendazole is used as an inhibitor of RAN in combination with an inhibitor of an epidermal growth factor receptor (EGFR) tyrosine kinase such as the small molecules gefitinib, erlotinib, afatinib, brigatinib, icotinib, or osimertinib or the antibodies cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab.
- EGFR inhibitors an enzyme that inhibit epidermal growth factor receptor (EGFR) tyrosine kinase.
- mebendazole and an EGFR inhibitor may be simultaneous, sequential or separate. It has been demonstrated that the combination of mebendazole and an EGFR inhibitor, namely gefitinib, has a synergistic effect against cancer cell proliferation (see Figure 1). It has also been shown that mebendazole can restore sensitivity of gefitinib resistant cancer cells to gefitinib treatment therefore providing a new therapeutic approach for the treatment of patients who have progressed on EGFR inhibitor therapy and, potentially, a new mechanism to prevent development of EGFR inhibitor resistance (see Figure 2).
- the Ran inhibitor mebendazole can eradicate the induction of Ran stimulated by the EGFR inhibitors gefitinib and osimertinib thus indicating that co-administration of a Ran inhibitor with a tyrosine kinase inhibitor may overcome or substantially delay acquired resistance to tyrosine kinase inhibitor therapy.
- Identification of the patients indicated for combination therapy with a Ran inhibitor and a tyrosine kinase inhibitor may involve testing for mutation status of a tyrosine kinase such as EGFR. Testing for tyrosine kinase expression/mutation status can be by the methods available in the art, for example the commercially available testing kits produced by Genzyme, QIAGEN and Argenomics S.A. for predicting response to the various tyrosine kinase inhibitors.
- mebendazole can down regulate C5a ( Figures 3 and 4). This finding indicates that mebendazole may be used to potentiate or promote an innate immune response to cancer cells/tumours.
- the invention thus provides mebendazole for use to potentiate or promote any innate immune response to cancer cells/tumours (i.e. as an immunotherapy) for the treatment of cancer via to its ability to down regulate C5a.
- the patient is a mammal and in most preferred cases the patient is a human patient.
- the mebendazole for use is administered in a dosage of from 1 to 5000 mg/day.
- the invention also relates to a method of treatment of a cancer that overexpresses RAN, or its protein product Ran or Ran mRNA, comprising a step of administering to a patient in need thereof an effective amount of mebendazole or a pharmaceutically acceptable form thereof.
- This method of treatment may further comprise a step of testing a sample obtained from said patient to determine whether said patient has a RAN overexpressing cancer prior to said administration step.
- the invention also provides a method of treatment of a cancer that overexpresses RAN, or its protein product Ran or Ran mRNA, comprising the step of administering to a patient who has been identified as having a cancer that overexpresses RAN, or its protein product Ran, an effective amount of mebendazole or a pharmaceutically acceptable form thereof.
- This method of treatment may further comprise a step of testing a sample obtained from said patient to determine whether said patient has a RAN overexpressing cancer prior to said administration step.
- the invention also provides a method of treatment of a cancer that overexpresses RAN, or its protein product Ran or Ran mRNA, comprising the steps of selecting a patient who has a cancer that overexpresses RAN or its protein product Ran or Ran mRNA, and administering an effective amount of mebendazole or a pharmaceutically acceptable form thereof to that patient.
- This method of treatment may further comprise a step of testing a sample obtained from said patient to determine whether said patient has a RAN overexpressing cancer prior to said administration step.
- the invention also provides a method of treatment for cancer in a patient diagnosed as having a cancer characterised by an overexpression of RAN or its protein product Ran or Ran mRNA involving administration to a patient in need thereof an effective amount of mebendazole.
- the cancer characterised by an overexpression of RAN may be triple negative breast cancer.
- the cancer characterised by an overexpression of RAN may be lung cancer, and in particular lung cancers that have previously been treated with a tyrosine kinase inhibitor, for example wherein the previous treatment involved administration of an tyrosine kinase inhibitor such as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor such as gefitinib, erlotinib, afatinib, brigatinib, icotinib or osimertinib to a lung cancer patient and wherein the disease no longer responds to the treatment with the EGFR inhibitor.
- EGFR epidermal growth factor receptor
- Such methods may involve coadministration of the previously used tyrosine kinase inhibitor with a Ran inhibitor, preferably wherein the Ran inhibitor is mebendazole.
- the invention also provides a method of treatment for cancer in a patient diagnosed as having a cancer characterised by an overexpression of a tyrosine kinase, such as a mutated epidermal growth factor receptor (EGFR) tyrosine kinase, involving administering mebendazole in combination with an inhibitor of the tyrosine kinase that is overexpressed, for example in a cancer with a mutation in the EGFR tyrosine kinase domain, an EGFR inhibitor may be used.
- the administration of mebendazole and an EGFR inhibitor may be simultaneous, sequential or separate.
- the combination of mebendazole and an EGFR inhibitor may prevent or substantially delay the emergence of resistance to the EGFR inhibitor associated with EGFR inhibitor monotherapy.
- the combination of mebendazole and an EGFR inhibitor may resensitize a tumour to treatment with an EGFR inhibitor to which the patient no longer responds as a monotherapy.
- the invention relates to the use of mebendazole, or a pharmaceutically acceptable form thereof, for the manufacture of a medicament for the treatment of cancer, wherein the cancer overexpresses RAN or its protein product Ran or wherein the cancer is indicated for tyrosine kinase inhibitor therapy.
- the resultant medicament may be provided in a package with instruction for use in the treatment of a cancer that overexpresses RAN or its protein product Ran or for use in combination with a tyrosine kinase inhibitor for the treatment of cancer.
- the medicament is to be used in combination with a second pharmacologically active agent the administration of mebendazole and the second pharmacologically active agent may be simultaneous, sequential or separate.
- the resultant, mebendazole containing medicament may be provided in a package with instruction for use in combination with an EGFR inhibitor such as gefitinib.
- the invention provides a package comprising mebendazole or a pharmaceutically acceptable form thereof and instructions for its use in the treatment of a cancer, wherein the cancer overexpresses RAN or its protein product Ran or Rna mRNA or instructions for its use in the treatment of a cancer that overexpresses a tyrosine kinase such as epidermal growth factor receptor (EGFR) tyrosine kinase.
- EGFR epidermal growth factor receptor
- the combination of mebendazole with a EGFR tyrosine kinase inhibitor can be used for the treatment of a cancer that is naive to EGFR treatment or that has previously been treated with an EGFR inhibitor, for example a cancer that has previously responded to treatment with a first EGFR inhibitor and that has subsequently developed resistance to that first EGFR inhibitor.
- a Ran inhibitor in combination with an EGFR inhibitor derives from the synergistic effect observed in combinations of mebendazole with gefitinib shown in Figures 1 and 2.
- mebendazole herein and above relates to mebendazole itself or a pharmaceutically acceptable form of mebendazole.
- Pharmaceutically acceptable forms of mebendazole include prodrugs of mebendazole, that is to say compounds which break down and/or are metabolised in vivo to provide an active compound of formula (I).
- General examples of prodrugs include simple esters, and other esters such as mixed carbonate esters, carbamates, glycosides, ethers, acetals and ketals.
- Prodrug motifs may, for example, be directly introduced at the benzimidazole NH position of mebendazole.
- references to pharmaceutically acceptable forms of mebendazole expressly include reference to known prodrugs of mebendazole, for example /V-alkoxycarbonyl prodrugs as described in Int J Pharmaceutics 1994 (10) p 231-239 that advantageously improve aqueous solubility and, as result, oral bioavailability of mebendazole.
- /V-methoxycarbonyl, /V-ethoxy carbonyl and N- propoxycarbonyl forms of mebendazole at the benzimidazole NH position of mebendazole), in their respective isomeric forms, are examples of prodrugs that are pharmaceutically acceptable forms of mebendazole.
- mebendazole include metabolites of mebendazole, in particular metabolites that retain an inhibitory effect on RAN transcription.
- a metabolite, as employed herein, is a compound that is produced in Vo from the metabolism of mebendazole, such as, without limitation, oxidative metabolites.
- mebendazole also include deuterated forms of mebendazole.
- Deuterated forms of mebendazole are derivatives of pimozide in which one or more aliphatic or aromatic hydrogen atom is substituted for a deuterium atom.
- a hydrogen atom at a site susceptible to metabolism may be replaced by a deuterium atom to reduce metabolism at that site.
- mebendazole examples include formulations of mebendazole, for example formulations that exhibit a pharmacological profile that is different to the clinical formulations presently in use for treatment of neurological conditions.
- mebendazole or a pharmaceutically acceptable form thereof, as an inhibitor of RAN transcription for use as a medicament.
- the present invention provides methods for treatment or alleviation of a cancer over expressing RAN, or its protein product Ran or Ran mRNA, in the tissue of one or more organs as mentioned herein, comprising the step of administering mebendazole or a pharmaceutically acceptable form thereof to a patient in need thereof.
- the method treatment is for patients with a cancer that have been diagnosed as having a cancer that overexpresses RAN or Ran or Ran mRNA.
- Such methods according to the present invention may comprise one or more steps of administration or release of an effective amount of mebendazole or a pharmaceutically acceptable form thereof, or a pharmaceutical composition comprising mebendazole or a pharmaceutically acceptable form thereof, to an individual in need thereof.
- steps of administration or release according to the present invention is simultaneous, sequential or separate.
- An individual in need as referred to herein may be an individual that benefits from the administration of a mebendazole or a pharmaceutically acceptable form thereof, in particular an individual with a cancer that overexpresses RAN or its protein product Ran or Ran mRNA.
- Such an individual in one embodiment suffers from a malignant neoplasm (tumour) in the tissue of one or more organs.
- the tumour(s) overexpresses Ran on treatment with a second pharmacologically active agent that induces RAN or its protein product Ran.
- the cancer may be selected from cancers of the breast, lung, ovary or kidney or a leukaemia.
- the cancer may be one in which the PI3K/Akt/mTORC1 and/or Ras/MEK/ERK pathways are activated.
- the cancer may be triple negative breast cancer.
- the individual may be any human being, male or female, infant, middle-aged or old.
- the individual may be a non-human mammal, for example a mammal from the members of the Canidae, Felinae, Bovidae, Equidae, Suidae, Camelini and Cervidae families.
- Identification of the patient to be treated in the methods of the invention can be achieved in a number of ways.
- the identification may involve analysis of a sample obtained from a patient, for example a blood sample or a tumour biopsy sample. Analysis of a patient blood sample may be performed by isolating the serum exosome and then carrying out an ELISA or quantitative real time PCR (q RT-PCR) analysis to provide the necessary tumour/patient classification.
- q RT-PCR quantitative real time PCR
- a tumour biopsy sample can be stained with a stain comprising a RAN selective antibody linked to a visualising means such as an enzyme or fluorophore.
- the stained tumour biopsy can then be categorised as a RAN overexpressing tumour or a non-RAN overexpressing tumour. This categorisation may be performed by a visual or automated scoring.
- scoring of Ran immunohistochemically stained tumour biopsy sample slides can be performed under a light microscope and that an assessment of the % of tumour cells staining over the whole section provides a method to identify tumours that overexpress RAN.
- treatment refers to the management and care of a patient for the purpose of combating a condition, disease or disorder.
- the term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of mebendazole or a pharmaceutically acceptable form thereof for the purpose of: alleviating or relieving symptoms or complications; delaying the progression of the condition, partially arresting the clinical manifestations, disease or disorder; curing or eliminating the condition, disease or disorder; and/or preventing or reducing the risk of acquiring the condition, disease or disorder, wherein "preventing” or “prevention” is to be understood to refer to the management and care of a patient for the purpose of hindering the development of the condition, disease or disorder, and includes the administration of the active compounds to prevent or reduce the risk of the onset of symptoms or complications.
- the patient to be treated is preferably a mammal, in particular a human being. Treatment of animals, such as mice, rats, dogs, cats, cows, horses, sheep and pigs, is, however, also within the scope of the present invention.
- the patients to be treated according to the present invention can be of various ages, for example, adults, children, children under 16, children age 6-16, children age 2-16, children age 2 months to 6 years or children age 2 months to 5 years.
- the invention is thus, in one embodiment, directed to mebendazole or a pharmaceutically acceptable form thereof for use in the treatment of cancer in the tissue of one or more organs of a mammal.
- said treatment is ameliorative and/or curative.
- said mammal is a human (homo sapiens).
- said organ is in one embodiment selected from the group consisting of breast, lung, ovarian, prostate, blood, brain and renal cancers
- Mebendazole or a pharmaceutically acceptable form thereof for use as described herein, for example in the treatment of cancer that overexpresses RAN, or its protein product Ran may be provided as a pharmaceutical composition comprising mebendazole or a pharmaceutically acceptable form thereof in combination with one or more pharmaceutically acceptable diluents or carriers.
- the formulation may be a formulation currently used in the clinic for mebendazole or may be a new formulation specifically adapted to the purpose of treating RAN overexpressing cancers or cancers indicated for tyrosine kinase inhibitor therapy.
- Diluents and carriers may include those suitable for parenteral, oral, topical, mucosal and rectal administration.
- the present invention also provides a process for preparing such a pharmaceutical composition (for example a pharmaceutical composition for parenteral, oral, topical, mucosal or rectal administration), said process comprising mixing the ingredients.
- compositions may be prepared e.g. for parenteral, subcutaneous, intramuscular or intravenous administration, particularly in the form of liquid solutions or suspensions; for oral administration, particularly in the form of tablets or capsules; for topical e.g. pulmonary or intranasal administration, particularly in the form of powders, nasal drops or aerosols and transdermal administration; for mucosal administration e.g. to buccal, sublingual or vaginal mucosa, and for rectal administration e.g. in the form of a suppository.
- compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA., (1985).
- Formulations for parenteral administration may contain as excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like.
- Formulations for nasal administration may be solid and may contain excipients, for example, lactose or dextran, or may be aqueous or oily solutions for use in the form of nasal drops or metered sprays.
- typical excipients include sugars, calcium stearate, magnesium stearate, pregelatinated starch, and the like.
- compositions suitable for oral administration may comprise one or more physiologically compatible carriers and/or excipients and may be in solid or liquid form.
- Tablets and capsules may be prepared with binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone (PVP); fillers, such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine; lubricants, such as magnesium stearate, talc, polyethylene glycol, or silica; and surfactants, such as sodium lauryl sulfate.
- binding agents for example, syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone (PVP); fillers, such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine; lubricants, such as magnesium stearate, talc,
- Liquid compositions may contain conventional additives such as suspending agents, for example sorbitol syrup, methyl cellulose, sugar syrup, gelatin, carboxymethyl-cellulose, or edible fats; emulsifying agents such as lecithin, or acacia; vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil; preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
- suspending agents for example sorbitol syrup, methyl cellulose, sugar syrup, gelatin, carboxymethyl-cellulose, or edible fats
- emulsifying agents such as lecithin, or acacia
- vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil
- preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
- BHA butylated hydroxyanisole
- BHT butylated hydroxytoluen
- Solid oral dosage forms include tablets, two-piece hard shell capsules and soft elastic gelatin (SEG) capsules.
- a dry shell formulation typically comprises of about 40% to 60% w/w concentration of gelatin, about a 20% to 30% concentration of plasticizer (such as glycerin, sorbitol or propylene glycol) and about a 30% to 40% concentration of water.
- plasticizer such as glycerin, sorbitol or propylene glycol
- Other materials such as preservatives, dyes, opacifiers and flavours also may be present.
- the liquid fill material comprises a solid drug that has been dissolved, solubilized or dispersed (with suspending agents such as beeswax, hydrogenated castor oil or polyethylene glycol 4000) or a liquid drug in vehicles or combinations of vehicles such as mineral oil, vegetable oils, triglycerides, glycols, polyols and surface-active agents.
- suspending agents such as beeswax, hydrogenated castor oil or polyethylene glycol 4000
- a liquid drug in vehicles or combinations of vehicles such as mineral oil, vegetable oils, triglycerides, glycols, polyols and surface-active agents.
- mebendazole or a pharmaceutically acceptable form thereof, for use or for use in a method of treatment as described herein, can be combined with or comprise one or more second active ingredients which are understood as other therapeutic compounds or pharmaceutically acceptable derivatives thereof.
- Methods for treatment according to the present invention may comprise one or more steps of administration of one or more second active ingredients, either concomitantly or sequentially, and in any suitable ratios.
- second active ingredients are, for example, selected from compounds used to treat or prevent cancer in the tissue of one or more organs or symptoms or used to treat or prevent complications associated with treatment of cancer in the tissue of one or more organs.
- second active ingredients may be intended for the treatment of the side effects associated with the primary treatment or may be aimed at overcoming or suppressing resistance that may arise in the cancer.
- the one or more second active ingredients may be directed to the treatment of cancer, the treatment or suppression of emesis, the blockage of drug efflux pumps or potentiation of the anti-cancer effect of mebendazole.
- a preferred class of second active ingredient for use in combination with mebendazole are tyrosine kinase inhibitors.
- the tyrosine kinase inhibitor may be as a small molecule or an antibody tyrosine kinase inhibitor.
- tyrosine kinase inhibitors that may be used in combination with a Ran inhibitor, for example mebendazole, for the treatment of cancer include afatinib (GiotrifTM), axitinib (InlytaTM), bosutinib (BosulifTM), crizotinib (XalkoriTM), dasatinib (SprycelTM), erlotinib (Tarceva), gefitinib (IressaTM), osimertinib (TagrissoTM), imatinib (GlivecTM), lapatinib (TyverbTM), nilotinib (TasignaTM), pazopanib (VotrientTM), regorafenib (StivargaTM), sorafenib (NexavarTM), sunitinib (SutentTM) and ibrutinib (ImbruvicaTM).
- Examples of EGFR tyrosine kinase inhibitors that may be used in combination with a Ran inhibitor, for example mebendazole, for the treatment of cancer include the small molecules gefitinib, erlotinib, afatinib, brigatinib, icotinib, and osimertinib and the antibodies cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab.
- Methods of treatment according to the present invention in embodiments include a step wherein mebendazole is administered simultaneously, sequentially or separately in combination with one or more second active ingredients.
- the action of the second therapeutic agent and mebendazole is synergistic.
- kits according to the present invention in one embodiment comprises mebendazole or a pharmaceutically acceptable form thereof or a composition thereof as defined herein for treatment of cancer in the tissue of one or more organs in combination with a further active ingredient as described herein, for example a tyrosine kinase inhibitor such as an inhibitor of EGFR.
- Kits according to the present invention in one embodiment allows for simultaneous, sequential or separate administration of mebendazole and one or more second active ingredients as described herein and are optionally provided with instructions therefore.
- the invention provides a package containing mebendazole or a pharmaceutically acceptable form thereof and instructions for its use for the treatment of cancer, for example for patients with a cancer that overexpresses RAN or its protein product Ran or that is indicated for tyrosine kinase inhibitor therapy.
- Administration and dosage for example for patients with a cancer that overexpresses RAN or its protein product Ran or that is indicated for tyrosine kinase inhibitor therapy.
- a composition comprising mebendazole or a pharmaceutically acceptable form thereof is in embodiments administered to a cancer patient having a cancer that overexpresses RAN or its protein product Ran in a pharmaceutically effective dose or a therapeutically effective amount.
- a composition comprising mebendazole or a pharmaceutically acceptable form thereof may be administered to a cancer patient that is receiving or that has already received tyrosine kinase inhibitor therapy.
- a therapeutically effective amount of mebendazole or a pharmaceutically acceptable form thereof according to the present invention is an amount sufficient to cure, prevent, reduce the risk of, alleviate or partially arrest the clinical manifestations of a cancer that overexpresses RAN or its protein product Ran or that has been or is being treated with tyrosine kinase inhibitor therapy.
- the amount that is effective will depend on the severity of the cancer as well as on the weight and general state of the subject. An amount adequate to accomplish this is defined as a "therapeutically effective amount”.
- the composition is administered in doses of from 1 mg/day to 5000 mg/day.
- Mebendazole or a pharmaceutically acceptable form thereof, may be administered as an oral formulation, for instance in the form of a tablet.
- the administration may be in the form a local infusion or injection, or an intravenous or subcutaneous injection depending on the location of the cancer to be treated.
- the route of administration allows for introducing mebendazole, or a pharmaceutically acceptable form thereof, for use into the blood stream to ultimately target the desired site(s) of action.
- the route of administration is any suitable route, such as an enteral route (including the oral, rectal, nasal, pulmonary, buccal, sublingual, transdermal, intracisternal and intraperitoneal administration), and/or a parenteral route (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal administration).
- an enteral route including the oral, rectal, nasal, pulmonary, buccal, sublingual, transdermal, intracisternal and intraperitoneal administration
- a parenteral route including subcutaneous, intramuscular, intrathecal, intravenous and intradermal administration.
- Appropriate dosage forms for such administration may be prepared by conventional techniques.
- Parenteral administration is any administration route not being the oral/enteral route whereby the medicament avoids first-pass degradation in the liver. Accordingly, parenteral administration includes any injections and infusions, for example bolus injection or continuous infusion, such as intravenous administration, intramuscular administration or subcutaneous administration. Furthermore, parenteral administration includes inhalations and topical administration.
- the composition may in embodiments be administered topically to cross any mucosal membrane of an animal to which the substance or peptide is to be given, e.g. in the nose, vagina, eye, mouth, genital tract, lungs, gastrointestinal tract, or rectum, for example the mucosa of the nose, or mouth, and accordingly, parenteral administration may also include buccal, sublingual, nasal, rectal, vaginal and intraperitoneal administration as well as pulmonal and bronchial administration by inhalation or installation. In some embodiments, the composition is administered topically to cross the skin.
- intravenous, subcutaneous and intramuscular forms of parenteral administration may be employed.
- the mebendazole composition according to the invention is used as a local treatment, i.e. is introduced directly to the site(s) of action. Accordingly, mebendazole may be applied to the skin or mucosa directly, or may be injected into the site of action, for example into the diseased tissue or to an end artery leading directly to the diseased tissue.
- mebendazole or a pharmaceutically acceptable form thereof according to the present invention or pharmaceutically acceptable derivatives thereof are administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses.
- the pharmaceutical compositions or compounds according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 20th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 2000.
- pharmaceutically acceptable form in present context includes pharmaceutically acceptable salts, which indicate a salt which is not harmful to the patient.
- Such salts include pharmaceutically acceptable basic or acid addition salts as well as pharmaceutically acceptable metal salts, ammonium salts and alkylated ammonium salts.
- a pharmaceutically acceptable derivative further includes esters and prodrugs, or other precursors of a compound which may be biologically metabolized into the active compound, or crystal forms of a compound.
- the pharmaceutical composition or pharmaceutically acceptable composition may be specifically formulated for administration by any suitable route, such as an enteral route, the oral, rectal, nasal, pulmonary, buccal, sublingual, transdermal, intracisternal, intraperitoneal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route.
- a suitable route such as an enteral route, the oral, rectal, nasal, pulmonary, buccal, sublingual, transdermal, intracisternal, intraperitoneal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route.
- compositions or compounds of the present invention are formulated for crossing the blood-brain-barrier.
- compositions for oral administration include solid dosage forms such as hard or soft capsules, tablets, troches, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings such as enteric coatings, or they can be formulated so as to provide controlled release of the active ingredient, such as sustained or prolonged release, according to methods well known in the art. In the same solid dosage form two active ingredients may be combined so as to provide controlled release of one active ingredient and immediate release of another active ingredient.
- Liquid dosage forms for oral administration include solutions, emulsions, aqueous or oily suspensions, syrups and elixirs.
- compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions, as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also regarded as being within the scope of the present invention.
- Suitable administration forms include suppositories, sprays, ointments, creams/lotions, gels, inhalants, dermal patches, implants, etc.
- Mebendazole for use according to the present invention is generally utilized as the free substance or as a pharmaceutically derivative such as a pharmaceutically acceptable salt thereof
- prodrug refers to derivatives of mebendazole that are rapidly transformed in vivo to yield mebendazole, for example, by hydrolysis in blood or by metabolism in cells, such as for example the cells of the basal ganglia.
- prodrugs include pharmaceutically acceptable, non-toxic esters of the compounds of the present invention.
- Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
- solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose.
- liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water.
- the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
- the pharmaceutical compositions formed by combining the compounds for use according to the present invention and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
- the formulations may conveniently be presented in unit dosage form by methods known in the art of
- Formulations of the present invention suitable for oral administration may be presented as discrete units, such as capsules or tablets, which each contain a predetermined amount of the active ingredient, and which may include a suitable excipient.
- compositions intended for oral use may be prepared according to any known method, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets may contain the active ingredient(s) in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may, for example, be: inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example, starch, gelatine or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in U.S. Patent Nos. 4,356, 108; 4, 166,452; and 4,265,874, the contents of which are incorporated herein by reference, to form osmotic therapeutic tablets for controlled release.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as a liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active compound in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol,
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agent.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known methods using suitable dispersing or wetting agents and suspending agents described above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol.
- Suitable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conveniently employed as solvent or suspending medium.
- any bland fixed oil may be employed using synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- compositions may also be in the form of suppositories for rectal administration of the compounds of the invention.
- These compositions can be prepared by mixing the compound with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will thus melt in the rectum to release the drug.
- suitable non-irritating excipient include, for example, cocoa butter and polyethylene glycols.
- the histogram of Figure 1 B shows the survival of HCC827 cells 24h after treatment with mebendazole, gefitinib and dasatinib, or with a combination of the Ran inhibitor mebendazole and a tyrosine kinase inhibitor with 100% survival being evaluated relative to the control (DMSO) treated cells.
- treatment with mebendazole at concentrations of 0.1 ⁇ and 0.5 ⁇ causes a ca 30% and 65% reduction in cell survival.
- Treatment with 1 ⁇ concentrations of gefitinib and dasatinib caused a ca 40 and 70 % reduction in survival, respectively, relative to control.
- mebendazole at a concentration of 0.1 ⁇ , was used in combination with gefitinib and dasatinib (each at 1 ⁇ ), a 70% and 80% reduction in cell survival was observed thus indicating a synergistic effect between the Ran inhibitor (mebendazole) and the tyrosine kinase inhibitors against the survival of human cancer cells.
- HCC827 GR5 gefitinib resistant
- HCC827 derived gefitinib resistant cell line HCC827 GR5 from Department for Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- HCC827 GR5 from Department for Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- FIG 2A the effects on morphology mirrored that observed with HCC827 with the exception of the gefitinib treated cohort that were largely unaffected by treatment.
- the lack of activity of gefitinib on the survival of these resistant cells at a concentration of 1 ⁇ can be clearly seen in figure 2B and this contrasts strongly to the 65% reduction in cell survival when gefitinib was administered with 0.1 ⁇ mebendazole.
- the enhancement in activity of dasatinib treatment when the drug was given in combination with mebendazole demonstrates once more the synergy that can be derived from dosing of a Ran inhibitor with a second type of tyrosine kinase inhibitor (a Bcr-Abl tyrosine kinase). Effect of Ran inhibitor treatment on the expression of mRNA
- Akt1 and Akt2 are members of the PI3K/mTOR pathway that is found to be hyperactive in most of common cancers and in 90% of tyrosine kinase resistant cancers.
- c-Met also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR) is a protein that in humans is encoded by the MET gene.
- the data was extracted from scanned images using NimbleScan and the Robust Multichip Average (RMA) algorithm was used to generate gene expression values.
- Microarray data was normalised using Robust Multichip Average (RMA) method and differentially expressed genes between RAN knock-down and Control were identified by ANOVA.
- were selected for pathway analysis using GeneGo MetaCore.
- EMT epithelial- to-mesenchymal transition
- microarray data showed thai
- PDK (PDPK1), p27KIP1 , PLC-gamma 2, A20
- tumour microenvironment is crucial for understanding cancer and is subject to varying levels of immunosurvei!!ance and immunosuppression. It is believed that the complement anaphyiatoxins C3a and C5a enhance tumour growth by shifting the balance toward immunosuppression, thus challenging longstanding dogma that complement activation is advantageous in cancer patients. Furthermore, the ability of neoplastic ceils to evade attack by complement proteins while simultaneously activating complement undermines traditional concepts of complement in tumour control. Numerous studies have investigated the relationship between local and/or systemic complement signalling, the host immune response, and tumour progression in experimental models of lymphoma and ovarian, mammary, breast, lung, and cervical cancer.
- C3a and/or C5a signalling modifies the immune infiltrate within the tumour microenvironment and/or the peripheral blood and lymphoid organs, with consequential effects on tumour growth.
- complement activation modulates the function or efficiency of several types of immune effector ceils.
- mebendazole to down regulate C5a thus provide the potential to promote or potentiate any innate immune response to cancer cells in addition to direct anti-tumour effects derived from its ability to inhibit Ran. Mebendazole may therefore be used as an immunotherapy due to its ability to down regulate C5a. Without being bound by theory, it is believed that downregulation of C5a causes upreguiaiion of T ceils and NK natural killer) cells therefore promoting/potentiating the immune response. Effect of Ran inhibitor treatment and tyrosine kinases inhibitor treatment on the expression of Ran and pBad in HCC827 GR5
- HCC827-GR5 cells in a quantity of 0.65 - 0,8 ⁇ 10 5 ) were seeded in a 10 cm petri dish and allowed to adhere overnight.
- the ceils were then treated as with (number correspond to the lane number of the Western Blots): 1) Control (DMSQ), 2) 1 ⁇ Gefiiinib, 3) 300 nM Osimertinib, 4) 100 nM mebendazole, 5) 100 nM mebendazole + 1 ⁇ Gefiiinib, 8) 100 nM mebendazole 5 + 300 nM Osimertinib, 7) 500 nM mebendazole, 8) 500 nM mebendazole + 1 ⁇ Gefiiinib, 9) 500 nM mebendazole + 300 nM Osimertinib.
- BAD is a member of the BCL-2 family.
- BCL-2 family members are regulators of the programmed cell death pathways.
- BAD induces apoptosis by inhibiting antiapoptotic BCL-2- family members - BCL-x, Bcl-2, thereby allowing two other pro-apoptotic proteins, BAK and BAX, to aggregate and induce release of cytochrome.
- Proapoptotic activity of this protein is regulated through its phosphorylation.
- Protein kinases AKT and MAP kinase, as well as protein phosphatase calcineurin were found to be involved in the regulation of this protein.
- the BAD protein is a pro-apoptotic member of the Bcl-2 family whose ability to heterodimerize with survival proteins such as Bci-X(L) and to promote cell death is inhibited by phosphorylation.
- Gefitinib treatment results in a reduction in pBad whereas osimertinib appears to have no effect, compared to control, on pBad in GR5 cells.
- Mebendazole at 500 nM alone and in combination increases the dephosphorylation of pBad, and thus increased apoptosis, whereas the effect of 100 nM mebendazole is small after 24 hr.
- the survival of the HCC827 cells ranges from ca 50 to 60 %.
- Treatment with 5 ⁇ pimozide causes a reduction in cell survival relative to control of approximately 40%.
- Treatment of HCC827 cells with gefitinib (at 300 nM) with a 5 ⁇ concentrations of pimozide causes a reduction in cell survival of ca 80%, thus illustrating a synergistic effect against cancer cell survival that is realised from the combination of a Ran inhibitor and a EGFR inhibitor (gefitinib).
- Figure 7 shows the effects of drug treatment for 24 h on the survival of gefitinib resistant HCC827 GR5 cells, a cell line that is derived from normal HCC827 human lung cancer cells (cf Figure 6).
- treatment with gefitinib in this instance at all of the concentrations evaluated causes no more than a 15% reduction in cell survival.
- Pimozide treatment (Figure 7B) causes a ca 30% reduction in cell survival at a concentration of 5 ⁇ .
- the combination of various concentrations of pimozide and gefitinib 300 nM meanwhile proved superior to either agent when they were presented as single agents.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des petites molécules inhibitrices de RAN à un niveau transcriptionnel et leur utilisation dans le traitement du cancer, en particulier de cancers, tels que le cancer du sein triple-négatif, qui ont été identifiés comme surexprimant le gène RAN ou son produit protéique ou l'ARNm du gène RAN. Les inhibiteurs selon l'invention sont particulièrement utiles pour le traitement de patients identifiés comme ayant une tumeur qui surexprime le gène RAN ou son produit protéique ou l'ARNm du gène RAN.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1701400.2 | 2017-01-27 | ||
GB1701400.2A GB2559162A (en) | 2017-01-27 | 2017-01-27 | Compound for use in medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018138510A1 true WO2018138510A1 (fr) | 2018-08-02 |
Family
ID=58462631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2018/050222 WO2018138510A1 (fr) | 2017-01-27 | 2018-01-26 | Mébendazole utilisé dans le traitement du cancer |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2559162A (fr) |
WO (1) | WO2018138510A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110585199A (zh) * | 2019-08-16 | 2019-12-20 | 华东理工大学 | 甲苯达唑在制备治疗急性t淋巴白血病药物中的应用 |
WO2022094480A1 (fr) * | 2020-11-02 | 2022-05-05 | Skymount Medical Us Inc. | Méthodes de traitement d'une maladie à coronavirus et composés associés |
CN115177590A (zh) * | 2022-04-20 | 2022-10-14 | 南昌大学抚州医学院 | 一种甲苯达唑类脂质体的制备方法及应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115721722B (zh) * | 2022-11-09 | 2024-01-05 | 浙江大学 | 一种治疗egfr-tki耐药的非小细胞肺癌的药物组合物 |
EP4537834A1 (fr) * | 2023-10-11 | 2025-04-16 | Eberhard Karls Universität Tübingen (Medizinische Fakultät) | Immunosuppression de précision en tant que prévention et thérapie pour une maladie du greffon contre l'hôte |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3120849A1 (fr) * | 2014-01-29 | 2017-01-25 | Keio University | Inhibiteur de prolifération de cellules souches cancéreuses et inducteur d'accumulation d'oxygène actif intracellulaire |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050038022A1 (en) * | 2001-03-26 | 2005-02-17 | Unisearch Limited | Method for treatment of cancer and compositions for use therein |
EP2156834A1 (fr) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Compositions pharmaceutiques ophtalmiques comprenant du Sorafenib pour le traitement de pathologies néoangiogéniques de l'ýil |
US20150065526A1 (en) * | 2013-09-05 | 2015-03-05 | Emory University | Overcoming acquired resistance to chemotherapy treatments through suppression of stat3 |
CN107635547B (zh) * | 2015-02-06 | 2021-06-25 | 约翰霍普金斯大学 | 用于治疗和预防肿瘤的甲苯哒唑多形体 |
-
2017
- 2017-01-27 GB GB1701400.2A patent/GB2559162A/en not_active Withdrawn
-
2018
- 2018-01-26 WO PCT/GB2018/050222 patent/WO2018138510A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3120849A1 (fr) * | 2014-01-29 | 2017-01-25 | Keio University | Inhibiteur de prolifération de cellules souches cancéreuses et inducteur d'accumulation d'oxygène actif intracellulaire |
Non-Patent Citations (9)
Title |
---|
ANONYMOUS: "Blocking Ran protein reverses resistance of lung and breast cancers", 4 October 2016 (2016-10-04), XP002779493, Retrieved from the Internet <URL:https://www.sciencedaily.com/releases/2016/10/161004111242.htm> [retrieved on 20180320] * |
H.-F. YUEN ET AL: "Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways", CLINICAL CANCER RESEARCH, vol. 18, no. 2, 16 November 2011 (2011-11-16), US, pages 380 - 391, XP055433723, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-11-2035 * |
HIU-FUNG YUEN ET AL: "Ran GTPase promotes cancer progression via Met receptormediated downstream signaling", ONCOTARGET, 3 October 2016 (2016-10-03), United States, XP055382563, ISSN: 1949-2553, DOI: 10.18632/oncotarget.12420 * |
KARACHALIOU NIKI ET AL: "Melanoma: oncogenic drivers and the immune system.", ANNALS OF TRANSLATIONAL MEDICINE, vol. 3, no. 18, 265, October 2015 (2015-10-01), pages 1 - 22, XP002779492, ISSN: 2305-5839, DOI: 10.3978/j.issn.2305-5839.2015.08.06 * |
NYGREN PETER ET AL: "Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 139, no. 12, December 2013 (2013-12-01), pages 2133 - 2140, XP002779488 * |
PANTZIARKA P ET AL: "Repurposing Drugs in Oncology (ReDO) - Mebendazole as an anti-cancer agent", ECANCERMEDICALSCIENCE, vol. 8, no. 1, 10 July 2014 (2014-07-10), CANCER INTELLIGENCE GBR, XP002779489, ISSN: 1754-6605 * |
SIMBULAN-ROSENTHAL CYNTHIA M ET AL: "Abstract 3860: The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma", CANCER RESEARCH, vol. 76, no. Suppl. 14, July 2016 (2016-07-01), & 107TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); NEW ORLEANS, LA, USA; APRIL 16 -20, 2016, XP002779490, DOI: 10.1158/1538-7445.AM2016-3860 * |
TAPAS MUKHOPADHYAY ET AL: "Mebendazole Elicits a Potent Antitumor Effect on Human Cancer Cell Lines Both in Vitro and in Vivo", CLINICAL CANCER RESEARCH, 1 September 2002 (2002-09-01), United States, pages 2963 - 2969, XP055317868, Retrieved from the Internet <URL:http://clincancerres.aacrjournals.org/content/8/9/2963.full-text.pdf> [retrieved on 20161109] * |
XIA FANG ET AL: "Tumor cell dependence on Ran-GTP-directed mitosis", CANCER RESEARCH, vol. 68, no. 6, March 2008 (2008-03-01), pages 1826 - 1833, XP002779491, ISSN: 0008-5472 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110585199A (zh) * | 2019-08-16 | 2019-12-20 | 华东理工大学 | 甲苯达唑在制备治疗急性t淋巴白血病药物中的应用 |
WO2022094480A1 (fr) * | 2020-11-02 | 2022-05-05 | Skymount Medical Us Inc. | Méthodes de traitement d'une maladie à coronavirus et composés associés |
CN115177590A (zh) * | 2022-04-20 | 2022-10-14 | 南昌大学抚州医学院 | 一种甲苯达唑类脂质体的制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
GB201701400D0 (en) | 2017-03-15 |
GB2559162A (en) | 2018-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7337805B2 (ja) | がんを処置する方法 | |
WO2018138510A1 (fr) | Mébendazole utilisé dans le traitement du cancer | |
JP6620338B2 (ja) | 低用量ナルトレキソンによるがん細胞の準備刺激 | |
CN105008394B (zh) | 治疗结肠直肠癌的方法 | |
KR20200014790A (ko) | 난소암의 치료에 사용되는 티노스타무스틴 | |
JP7612763B2 (ja) | 癌治療 | |
Yokoyama et al. | A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402) | |
CN113164779A (zh) | 治疗cdk4/6抑制剂耐药性癌症的方法 | |
US20200248273A1 (en) | Treatment of squamous cell carcinoma | |
US10512641B2 (en) | Chloroquine induction par-4 and treatment of cancer | |
CN115867669A (zh) | 监测kras突变的方法 | |
Phillip et al. | Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines | |
Zhou et al. | SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER+ breast cancer models | |
JP7311902B2 (ja) | 前立腺がんの予防又は治療剤 | |
US11241442B2 (en) | Methods of use for TRP channel antagonist-based combination cancer therapies | |
US10106853B2 (en) | CUL4B as predictive biomarker for cancer treatment | |
Zhao et al. | PI3K/mTOR inhibitor VS-5584 combined with PLK1 inhibitor exhibits synergistic anti-cancer effects on non-small cell lung cancer | |
Shin et al. | Serum 25-hydroxyvitamin D levels correlate with EGFR mutational status in pulmonary adenocarcinoma | |
US20220040173A1 (en) | Methods of delaying pain progression and treating prostate cancer | |
US20210145811A1 (en) | Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype | |
US20240398814A1 (en) | Kras inhibitor and hdac inhibitor combination for the treatment of cancer | |
WO2015153866A1 (fr) | Thérapie anticancéreuse basée sur le ganetespib et un inhibiteur de l'egfr | |
WO2018065771A1 (fr) | Inhibiteur de ran au niveau transcriptionnel destiné à être utilisé dans le traitement du cancer | |
US20230338347A1 (en) | New Use of Inhibitors of the Notch Signalling Pathway | |
EP3326624A1 (fr) | Immunothérapie pour le cancer exprimant le casr (par ex., neuroblastome) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18702799 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18702799 Country of ref document: EP Kind code of ref document: A1 |